E
Evelien P. Mauser-Bunschoten
Researcher at Utrecht University
Publications - 123
Citations - 6233
Evelien P. Mauser-Bunschoten is an academic researcher from Utrecht University. The author has contributed to research in topics: Haemophilia & Hepatitis C. The author has an hindex of 35, co-authored 121 publications receiving 5673 citations. Previous affiliations of Evelien P. Mauser-Bunschoten include University Medical Center Utrecht.
Papers
More filters
Journal ArticleDOI
Guidelines for the management of hemophilia.
A. Srivastava,A. K. Brewer,Evelien P. Mauser-Bunschoten,Nigel S. Key,Steve Kitchen,Adolfo Llinás,C. A. Ludlam,Johnny Mahlangu,K. Mulder,M.-C. Poon,Alison Street +10 more
TL;DR: These evidence‐based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion‐transmitted infections.
Journal ArticleDOI
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study
I. Plug,J. G. van der Bom,J. G. van der Bom,M. Peters,Evelien P. Mauser-Bunschoten,A. de Goede-Bolder,L. Heijnen,Cees Smit,José Willemse,Frits R. Rosendaal +9 more
TL;DR: In this paper, the authors studied the mortality, causes of death, and life expectancy of hemophilia patients between 1992 and 2001, compared with those of previous cohorts, together spanning the periods before, during, and after the use of potentially contaminated clotting products.
Journal ArticleDOI
Sexual transmission of hepatitis C virus
Dorine Bresters,H. W. Reesink,C. L. Van Der Poel,H. T. M. Cuypers,P. N. Lelie,Evelien P. Mauser-Bunschoten,G. Roosendaal,H. M. Van Den Berg,R. A. F. M. Chamuleau,Peter L.M. Jansen,C.J. Weegink +10 more
TL;DR: This study, with the most sensitive techniques for detection of HCV, indicates that the risk of sexual transmission ofHCV is absent or very low.
Journal ArticleDOI
Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome
Krista Fischer,J. G. van der Bom,P. Molho,Claude Negrier,Evelien P. Mauser-Bunschoten,G. Roosendaal,P. de Kleijn,Diederick E. Grobbee,H. M. Van Den Berg +8 more
TL;DR: It is suggested that, compared with a primarily on‐demand treatment strategy, a primarily prophylactic treatment strategy leads to better outcome at equal treatment costs in young adults with severe haemophilia.
Journal ArticleDOI
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Corien L. Eckhardt,Alice S. van Velzen,Marjolein Peters,Jan Astermark,Paul P. T. Brons,Giancarlo Castaman,Marjon H. Cnossen,Natasja Dors,Carmen Escuriola-Ettingshausen,Karly Hamulyák,Daniel P. Hart,Charles R. M. Hay,Saturnino Haya,Waander L. van Heerde,Cedric Hermans,Margareta Holmström,Víctor Jiménez-Yuste,Russell Keenan,Robert Klamroth,Britta A P Laros-van Gorkom,Frank W.G. Leebeek,Ri Liesner,Anne Mäkipernaa,Christoph Male,Evelien P. Mauser-Bunschoten,Maria Gabriella Mazzucconi,Simon McRae,Karina Meijer,Michael J. Mitchell,Massimo Morfini,M.R. Nijziel,Johannes Oldenburg,Kathelijne Peerlinck,Pia Petrini,H Platokouki,Sylvia Reitter-Pfoertner,Elena Santagostino,Piercarla Schinco,Frans J. Smiers,B. Siegmund,Annarita Tagliaferri,Thynn Thynn Yee,Pieter Willem Kamphuisen,Johanna G. van der Bom,Karin Fijnvandraat +44 more
TL;DR: The INSIGHT study analyzed the association between F8 mutation and inhibitor development in patients with nonsevere hemophilia A and found that among a total of 214 different F8 missense mutations 19 were associated with inhibitor development.